Baxter (BAX) Launches Arisure Closed System Transfer Device

In a bid to promote safe handling of hazardous drugs and maintain medication sterility, Baxter International Inc. (NYSE:BAX) recently announced a distribution agreement for the launch of the Arisure Closed System Transfer device in the United States. The platform prevents contamination of intravenous (IV) medication delivery system during drug preparation.

Per management, with the latest development, Baxter will be able to ensure safer drug preparation, transportation, administration and disposal. The system will reduce the risk of accidental exposure or contamination, for both patients and caregivers.

The Arisure Closed System Transfer device includes a closed vial adapter, an intravenous dry spike and a closed male Luer valve. The Arisure Closed Male Luer lowers the exposure risk of healthcare professionals to sharp needles. Further, the Arisure Closed Male Luer is compatible with Baxter’s ONE-LINK Needle-free IV Connector and CLEARLINK Luer Activated Valve that paves way to initiate a mechanically and microbiologically closed system.

Broad Product Spectrum

Baxter has an impressive product portfolio with convenient kidney dialysis solutions, regenerative tissue products and the next-generation SIGMA Spectrum Infusion pump. The Sigma Spectrum Infusion System minimizes patient risk when administering vital fluids and medications. Recently, the company upgraded the SIGMA Spectrum Infusion System with the launch of DeviceVue Advanced Asset Tracking System.

Baxter International Inc. Price

Baxter International Inc. Price | Baxter International Inc. Quote

Baxter is the first and only smart infusion pump manufacturer to offer a tagless, end-to-end acid tracking application designed in consultation with potential customers to drive operational efficiencies and maximize the clinical value of their pump investments.

Of late, Baxter’s needle-free connector product lines have also been under focus, in which minimize hospital infections.

In acute therapies, Baxter launched the first 3-in-1 oXIRIS for continuous renal replacement therapy and sepsis management protocols. This adds to Baxter's multi-organ therapy offering, utilizing the Prismaflex system.

Stock Performance Solid

Over the past six months, Baxter has gained 9.8% comparing favorably with the industry’s rally of 5.7%. Baxter is poised to gain from an expanding product portfolio and increasing penetration in international markets. Accretive acquisitions like these are also key catalysts in the long haul. The company’s long-term expected earnings growth rate of 12.3% holds promise in this regard.

Zacks Rank & Key Picks

Baxter has a Zacks Rank #3 (Hold).

A few better-ranked stocks in the broader medical sector are Integer Holdings Corporation (NYSE:ITGR) , Bio-Rad Laboratories, Inc. (NYSE:BIO) and Intuitive Surgical, Inc. (NASDAQ:ISRG) .

Bio-Rad Laboratories flaunts a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here. The company has a long-term expected earnings growth rate of 25%.

Integer Holdings has a long-term expected earnings growth rate of 15%. The stock carries a Zacks Rank #2 (Buy).

Intuitive Surgical has a long-term expected earnings growth rate of 9.2%. The stock carries a Zacks Rank #2.

Wall Street’s Next Amazon (NASDAQ:AMZN)

Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.

Click for details >>